Topical Minoxidil: What to Expect, Week-by-Week First Month
At a glance
- Men's 5% solution / 1 mL with the dropper twice a day on the vertex, men only [1]
- Women's 5% foam / half a capful once daily [2]
- Earliest results the labels mention / 2 months for men on twice-daily solution, 3 months for women on once-daily foam [1][2]
- Longer wait the labels allow / at least 4 months for some men and at least 6 months for some women [1][2]
- If you stop / hair loss begins again [1]
- 5% vs 2% in men / 5% solution beat 2% and placebo on nonvellus hair count at 48 weeks [3]
- 5% foam vs placebo / higher hair counts at 16 weeks in 352 men [4]
- Where it is labeled to work / top of the scalp only, not frontal baldness or a receding hairline [1]
Does anything change in the first month?
Visible regrowth may not appear in the first month. The men's 5% solution label says results may occur at 2 months with twice-daily use, and that some men may need at least 4 months before they see results [1]. The women's 5% foam label says results may occur at 3 months with once-daily use, and that some women may need at least 6 months [2].
Month one is mainly about following the labeled schedule and noting whether scalp irritation or other listed symptoms occur. The label says continued use is necessary to increase and keep hair regrowth, that using more or more often will not improve results, and that hair loss will begin again if use stops [1][2].
Week 1: dose, application and scalp tolerance
The men's 5% solution is applied as 1 mL with the dropper twice a day, directly onto the scalp in the hair loss area [1]. That label restricts the product to men and to the top of the scalp (vertex), and states it is not intended for frontal baldness or a receding hairline [1]. The women's 5% foam is half a capful once daily, massaged into the scalp with the fingers, then hands washed well [2].
Label points that come up in week one:
- For external use only, with care to avoid the eyes; accidental eye contact is rinsed with large amounts of cool tap water [1][2].
- The men's 5% solution label says it is flammable and to keep it away from fire or flame. The women's foam label says it is extremely flammable and to avoid fire, flame or smoking during and immediately following application [1][2].
- The labels say not to use the product if the scalp is red, inflamed, infected, irritated or painful, or if other medicines are being used on the scalp [1][2].
Scalp irritation or redness is on both labels' stop-use lists [1][2]. In the longer trials, pruritus and local irritation were reported more often with 5% than with 2%: in the 48-week study of 393 men [3], and, along with hypertrichosis, in the 48-week study of 381 women, where 5% was also compared with placebo [5].
Weeks 2 to 4: what about shedding?
The stop-use and warning lists on these labels do not include shedding. In animal studies, topical minoxidil shortened telogen, causing premature entry of resting hair follicles into anagen, and the review authors say it probably has a similar action in humans [6]. That finding does not establish when or how much shedding a person will notice.
The labels' stop-use list covers scalp irritation or redness, unwanted facial hair growth, chest pain, rapid heartbeat, faintness or dizziness, sudden unexplained weight gain, and swelling of the hands or feet [1][2].
When results actually appear
Trials measured hair growth over longer periods than one month:
- 5% foam versus placebo, 16 weeks, 352 men aged 18 to 49: hair counts increased significantly compared with placebo (P<.0001). A total of 143 men continued into an open-label safety phase out to 52 weeks, and no efficacy data were collected past 16 weeks [4].
- 5% solution versus 2% versus placebo, 48 weeks, 393 men aged 18 to 49 (5% n=157, 2% n=158, placebo n=78), applied twice daily: 5% was significantly superior to both 2% and placebo on change from baseline in nonvellus hair count, patient rating of scalp coverage and treatment benefit, and investigator rating of scalp coverage [3].
- 5% versus 2% versus placebo in women, 48 weeks, 381 women aged 18 to 49 (5% n=153, 2% n=154, placebo n=74), applied twice daily: 5% was superior to placebo on all three primary measures and superior to 2% on patient-rated treatment benefit [5].
Is 5% better than 2%?
In men, yes: the 48-week trial found the 5% solution superior to the 2% solution and to placebo on nonvellus hair count and on patient and investigator ratings, with response occurring earlier at 5% [3]. In women, 5% beat placebo on all three primary measures and beat 2% on patient-rated treatment benefit, while 2% beat placebo only on hair count and investigator-rated hair growth [5].
The 5% solution is labeled for men only; the 5% product labeled for women is the foam, used once daily [1][2]. The 5% foam in the 16-week men's trial used a propylene glycol-free vehicle [4].
What happens if you stop
The label is explicit that continued use is necessary to increase and keep hair regrowth, or hair loss will begin again [1].
Keeping the product away from children and pets
In January 2026, FDA approved labeling supplements for the Rogaine products that add statements on cartons, containers and consumer booklets to keep the product out of reach of pets and to avoid contact between children and minoxidil application sites [7].
Frequently asked questions
Will I see new hair in the first month?
What do the labels say about shedding in weeks 2 to 4?
Can women use the 5% solution?
Does topical minoxidil work on a receding hairline?
What happens when I stop using it?
Is 5% stronger than 2%?
References
- U.S. National Library of Medicine, DailyMed. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue prescribing information. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue label
- U.S. National Library of Medicine, DailyMed. Women's Rogaine minoxidil 5% topical foam, Kenvue prescribing information. Women's Rogaine minoxidil 5% topical foam, Kenvue label
- Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-85. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men
- Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767-74. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men
- Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-53. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss
- Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186-94. Minoxidil: mechanisms of action on hair growth
- U.S. Food and Drug Administration. U.S. Food and Drug Administration